
|Articles|May 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 5
- Volume 15
- Issue 5
Novartis Seeks Approval for Gleevec in Four Rare Cancers
Novartis Seeks Approval for Gleevec in Four Rare Cancers
Advertisement
EAST HANOVER, New JerseyNovartis has submitted supplemental NDAs for imatinib (Gleevec) as treatment for four rare types of cancer. The diseases, all with Gleevec-sensitive pathways, are dermatofibrosarcoma protuberans, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and systemic mastocytosis.
Articles in this issue
about 20 years ago
NCCN Soft-Tissue Extremity Sarcoma Guidelines Clarify Follow-up Scheduleabout 20 years ago
Genentech Files sBLA for Avastin for First-Line NSCLC Treatmentabout 20 years ago
RFA Effective for Single, Small Hepatocellular Carcinomaabout 20 years ago
New Imaging, ChemoRT Recommendations From NCCNabout 20 years ago
Panitumumab Improves PFS in Advanced Colon Caabout 20 years ago
Studies Question Watchful Waiting for Some Prostate Ca Ptsabout 20 years ago
Growing Evidence Supports Stem Cell Hypothesis of Cancerabout 20 years ago
FDA Approves New Every-3-Week Dosing for Aranespabout 20 years ago
Telephone Often Delivers News of Breast Cancer Diagnosisabout 20 years ago
IND Submitted for CYT-500Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview
4
How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?
5













































































